Results 21 to 30 of about 25,109 (253)

Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer

Cancer Biology & Therapy, 2022
Prolylcarboxypeptidase (PRCP) is a lysosomal serine protease that cleaves peptide substrates when the penultimate amino acid is proline. Previous studies have linked PRCP to blood-pressure and appetite control through its ability to cleave peptide ...
Lei Duan, Sarah J. Calhoun, Ricardo E. Perez, Virgilia Macias, Fatima Mir, Paolo Gattuso, Carl G. Maki   +6 more
doaj   +1 more source

Pharmacological targeting of the pseudokinase Her3 [PDF]

Nature Chemical Biology, 2014
Her3 (also known as ErbB3) belongs to the epidermal growth factor receptor tyrosine kinases and is well credentialed as an anti-cancer target but is thought to be 'undruggable' using ATP-competitive small molecules because it lacks appreciable kinase activity. Here we report what is to our knowledge the first selective Her3 ligand, TX1-85-1, that forms
Ting Xie, Sang Min Lim, Kenneth D Westover, Michael E Dodge, Dalia Ercan, Scott B Ficarro, Durga Udayakumar, Deepak Gurbani, Hyun Seop Tae, Steven M Riddle, Taebo Sim, Jarrod A Marto, Pasi A Jänne, Craig M Crews, Nathanael S Gray   +14 more
openaire   +3 more sources

Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. [PDF]

PLoS ONE, 2013
Nuclear localized HER family receptor tyrosine kinases (RTKs) have been observed in primary tumor specimens and cancer cell lines for nearly two decades.
Toni M Brand, Mari Iida, Neha Luthar, Matthew J Wleklinski, Megan M Starr, Deric L Wheeler   +5 more
doaj   +1 more source

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma

Journal of Translational Medicine, 2021
Background Compared to the other members of human epidermal growth factor family receptors (HER), the role of HER3 has not been well defined in laryngeal cancer.
Giovanni Almadori, Antonella Coli, Eugenio De Corso, Dario Antonio Mele, Stefano Settimi, Giovanni Di Cintio, Francesca Brigato, Domenico Scannone, Thomas E. Carey, Gaetano Paludetti, Libero Lauriola, Franco Oreste Ranelletti   +11 more
doaj   +1 more source

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Cancer Discovery, 2021
In a phase I dose escalation/expansion study, use of the HER3-DXd antibody drug conjugate showed clinical activity in EGFR TKI-resistant, EGFR-mutant non–small cell lung cancer, presenting a future option for drug-resistant cancers.
P. Janne, C. Baik, Wu-Chou Su, M. Johnson, H. Hayashi, M. Nishio, Dong-Wan Kim, M. Koczywas, K. Gold, C. Steuer, H. Murakami, J. Yang, Sang-We Kim, M. Vigliotti, R. Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, D. Sternberg, Channing Yu, H. Yu   +20 more
semanticscholar   +1 more source

New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer

MedComm – Oncology, 2022
Human epidermal growth factor receptor 3 (HER3) is a member of the transmembrane receptor tyrosine kinase family. Upregulation of HER3 pathway has been implicated as a mechanism of resistance in solid tumors, particularly in estrogen receptor positive ...
Yasar Ahmed, Thamir Mahgoub, Maha Al Sindi, José J. Berenguer‐Pina   +3 more
doaj   +1 more source

Activating HER3 mutations in breast cancer [PDF]

Oncotarget, 2018
Recent studies have highlighted a role of HER3 in ER and HER2-driven breast cancers. We sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast cancer cells using ectopic expression of HER3 mutants. We found that HER3T355I mutant is activating with increased cell proliferation in ER+ T47D and MCF-7 breast cancer cells ...
Mishra, Rosalin, Alanazi, Samar, Yuan, Long, Solomon, Thomas, Thaker, Tarjani M., Jura, Natalia, Garrett, Joan T.   +6 more
openaire   +2 more sources

Frequent overexpression of HER3 in brain metastases from breast and lung cancer.

Clinical Cancer Research, 2023
PURPOSE HER3 belongs to a family of receptor tyrosine kinases with oncogenic properties and is targeted by a variety of novel anticancer agents. There is a huge unmet medical need for systemic treatment options in patients with brain metastases (BM ...
E. Tomasich, A. Steindl, C. Paiato, T. Hatziioannou, M. Kleinberger, L. Berchtold, R. Puhr, J. Hainfellner, L. Müllauer, G. Widhalm, F. Eckert, R. Bartsch, G. Heller, M. Preusser, A. Berghoff   +14 more
semanticscholar   +1 more source

Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives

Cancer Biology & Medicine, 2022
Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with the emergence of oncogene targeted therapies, treatment options have tremendously improved. Owing to their biological relevance, members of the ERBB receptor family,
Tobias Boch, Jens Köhler, Melanie Janning, Sonja Loges   +3 more
doaj   +1 more source

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.

Future Oncology, 2023
Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients.
H. Yu, Jie Yang, H. Hayashi, Y. Goto, E. Felip, M. Reck, M. Vigliotti, Qian Dong, F. Cantero, P. Fan, M. Kanai, D. Sternberg, P. Jänne   +12 more
semanticscholar   +1 more source